Heartache for Syndax
Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.
ASH 2024 preview – menin inhibitors face off again
Kura will see more combo data, while a new contender from Sumitomo emerges.
Vincerx stalls again
The group reports responses with its CD123-targeting ADC, but cash is running short.
The pieces of Vor’s puzzle start to come together
The depressed company could use Mylotarg as a stepping stone in AML.
A Prelude to a Lilly duel
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.
